Pharming vs Ultragenyx Pharmaceutical
PHAR and RARE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PHAR and RARE compare
Pharming grew revenue faster over the last twelve months (26.6% versus 15.8% for Ultragenyx Pharmaceutical).
Pharming keeps more of each dollar of sales as profit, with a net margin of 0.76% compared with −71.8% at Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical scores higher on the StockData Score (9 against 8 for Pharming), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PHAR | RARE |
|---|---|---|
| Size and price | ||
| Market cap | – | $1.6B |
| Share price | $13.40 | $16.70 |
| Change, 1 year | −23.6% | −47.7% |
| Change, 5 years | 55.5% | −78.9% |
| Beta (5Y) | 0.56 | 1.08 |
| Employees | 50K | 1,371 |
| StockData Score | ||
| Total score | 8 | 9 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 | 2 |
| Performance score | 1 | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 2.3× |
| FCF yield | – | −26.8% |
| Growth | ||
| Revenue growth (TTM) | 26.6% (better) | 15.8% |
| Revenue growth, 5Y average | 12.1% | 19.9% (better) |
| EPS growth, 5Y average | −40.8% | – |
| Profitability | ||
| Gross margin | 87.9% | – |
| Operating margin | 6.9% (better) | −64.0% |
| Net margin | 0.76% (better) | −71.8% |
| FCF margin | 14.3% (better) | −60.5% |
| Financial health | ||
| Interest coverage | 132× | – |
| Current ratio | 2.59 (better) | 1.40 |
| Altman Z-score | – | −5.70 |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.32% | 108% |
| Held by insiders | 0.00% | 4.0% |
| Insider net buying, 12 months | – | −$3.8M |
| Short interest, % of float | – | 25.0% |
Go deeper
- PHAR stock overview
- PHAR income statement
- PHAR valuation and score
- RARE stock overview
- RARE income statement
- RARE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.